Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

VRCA

Verrica Pharmaceuticals Inc

May 15 • 04:00PM ET

9.10

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SURI VTWO RYLD IWC VTWG GSSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.75	Insider Own	39.25%	Shs Outstand	42.41M	Perf Week	19.58%
Market Cap	386.02M	Forward P/E	-	EPS next Y	-0.91	Insider Trans	13.06%	Shs Float	25.77M	Perf Month	30.00%
Income	-80.74M	PEG	-	EPS next Q	-0.41	Inst Own	41.59%	Short Float	14.06%	Perf Quarter	72.35%
Sales	8.91M	P/S	43.32	EPS this Y	-1.80%	Inst Trans	-9.35%	Short Ratio	19.43	Perf Half Y	202.33%
Book/sh	0.04	P/B	255.33	EPS next Y	39.87%	ROA	-119.65%	Short Interest	3.62M	Perf Year	49.18%
Cash/sh	1.15	P/C	7.89	EPS next 5Y	-	ROE	-243.34%	52W Range	2.86 - 11.41	Perf YTD	24.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.97%	ROI	-171.98%	52W High	-20.25%	Beta	1.79
Dividend TTM	-	Quick Ratio	3.04	Sales past 5Y	-13.60%	Gross Margin	76.09%	52W Low	218.18%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	3.17	EPS Y/Y TTM	-162.67%	Oper. Margin	-838.45%	RSI (14)	74.11	Volatility	14.23% 7.36%
Employees	100	Debt/Eq	30.75	Sales Y/Y TTM	3.18%	Profit Margin	-905.83%	Recom	1.00	Target Price	15.50
Option/Short	Yes / Yes	LT Debt/Eq	30.09	EPS Q/Q	-185.51%	Payout	-	Rel Volume	0.00	Prev Close	9.10
Sales Surprise	27.29%	EPS Surprise	-6.41%	Sales Q/Q	10240.54%	Earnings	May 13 BMO	Avg Volume	186.46K	Price	9.10
SMA20	21.84%	SMA50	40.77%	SMA200	77.43%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
11:53AM	Loading…
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
09:10AM	Loading…
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
07:30AM	Loading…
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%
Oct-25-23 07:00AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 08:30AM	Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises (GlobeNewswire)
Aug-23-23 07:30AM	Verrica Issues Statement in Support of FDAs Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Aug-10-23 04:05PM	Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Aug-08-23 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:30AM	Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Associations (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Jul-27-23 06:06AM	Verrica Pharmaceuticals Chairman of the Board Acquires 1.3% More Stock (Simply Wall St.)
Jul-26-23 04:05PM	Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed (GlobeNewswire)
Jul-25-23 07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-24-23 03:16PM	Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday (Motley Fool) -31.46%
07:00AM	Following FDA Approval of YCANTH for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET (GlobeNewswire)
Jul-21-23 04:47PM	UPDATE 2-Verrica's drug gets US nod as first treatment for a type of skin infection (Reuters)
04:30PM	US FDA approves Verrica's skin disease treatment (Reuters)
04:24PM	Verrica Pharmaceuticals Announces FDA Approval of YCANTH (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum (GlobeNewswire)
Jul-17-23 07:22AM	With a 39% stake, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have a lot riding on the company (Simply Wall St.) +6.43%
Jul-12-23 03:16AM	Net Asset Value(s) (Business Wire)
May-31-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York (GlobeNewswire) +6.58%
May-30-23 12:34PM	We're Not Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn (Simply Wall St.) -7.48%
May-10-23 07:30AM	Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
06:11AM	Verrica Pharmaceuticals First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-09-23 07:30AM	Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 09:07AM	The past three years for Verrica Pharmaceuticals (NASDAQ:VRCA) investors has not been profitable (Simply Wall St.)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-12-23 07:00AM	Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Apr-11-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-23 07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 04:05PM	Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire) -5.47%
Feb-22-23 11:49AM	Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrants (American City Business Journals)
Feb-21-23 07:22AM	Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +5.56%
Feb-17-23 06:43PM	12 Most Promising Micro-Cap Stocks According to Analysts (Insider Monkey) +8.34%
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-24-23 07:30AM	Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire)
07:16AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have significant skin in the game with 40% ownership (Simply Wall St.)
Jan-04-23 07:30AM	Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions (GlobeNewswire) +14.93%
Jan-01-23 08:16AM	Bullish insiders bet US$11m on Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) (Simply Wall St.)
Dec-12-22 12:07PM	We're Not Very Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Rate (Simply Wall St.)
Nov-26-22 07:00AM	Investors in Verrica Pharmaceuticals (NASDAQ:VRCA) have unfortunately lost 83% over the last three years (Simply Wall St.)
Nov-07-22 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-31-22 04:30PM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +8.89%
Aug-17-22 07:53AM	Is Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Popular Amongst Insiders? (Simply Wall St.)
Aug-11-22 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) +5.22%
Aug-04-22 01:38PM	Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
12:34PM	Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
Aug-03-22 12:02PM	United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
Aug-01-22 07:30AM	Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan (GlobeNewswire) -6.35%
Jul-20-22 12:00PM	Verrica Pharmaceuticals Inc. (VRCA) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.61%
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada (Zacks)
Jul-07-22 06:10AM	Insider Buying: The Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Chairman of the Board Just Bought 46% More Shares (Simply Wall St.) +10.62%
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +9.20%
Jul-01-22 09:36AM	Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options (American City Business Journals) +13.02%
Jun-29-22 09:23PM	Verrica Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -6.87%
04:01PM	Verrica Announces Proposed Public Offering of Common Stock (GlobeNewswire)
03:26PM	Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter (Benzinga)
Jun-28-22 07:30AM	Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum (GlobeNewswire) +6.88%
Jun-17-22 09:35AM	Down 65% in 4 Weeks, Here's Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc. (VRCA) (Zacks) +8.70%
Jun-13-22 09:55AM	Here's Why Verrica Pharmaceuticals Inc. (VRCA) Could be Great Choice for a Bottom Fisher (Zacks)
Jun-05-22 08:42AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders recover some losses but still US$354k away from matching original investment (Simply Wall St.)
Jun-01-22 09:35AM	Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 Weeks (Zacks) -6.22%
May-26-22 03:37PM	Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA (Zacks)
May-25-22 03:14PM	RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next? (Benzinga) -63.85%
08:18AM	Verrica's stock slides after getting second complete response letter from FDA (MarketWatch)
06:39AM	Why Verrica Pharma Shares Are Plunging Today (Benzinga)
May-24-22 09:12PM	UPDATE 1-U.S. FDA declines to authorize Verrica's viral skin disease treatment (Reuters) -11.75%
08:00PM	Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC (GlobeNewswire)
May-17-22 11:53AM	KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M (Zacks)
May-16-22 09:35AM	After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA) (Zacks) +6.89%

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 29 '23	Buy	7.24	115,774	838,204	7,099,182	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 28 '23	Buy	7.08	126,116	892,901	6,983,408	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 27 '23	Buy	7.20	79,726	574,027	6,857,292	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 26 '23	Buy	6.49	54,652	354,691	6,777,566	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 22 '23	Buy	6.67	250,000	1,667,500	6,722,914	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 21 '23	Buy	6.17	200,000	1,234,000	6,472,914	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 19 '23	Buy	5.36	277,008	1,484,763	6,272,914	Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 18 '23	Buy	5.41	456,923	2,471,953	5,995,906	Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 15 '23	Buy	5.97	500,000	2,985,000	5,538,983	Dec 19 05:52 PM
Hayes Christopher G.	Chief Legal Officer	Nov 15 '23	Sale	2.97	11,558	34,327	123,226	Nov 16 04:32 PM
White Ted	President and CEO	Nov 15 '23	Sale	2.97	11,558	34,327	170,090	Nov 16 04:33 PM
Bonaccorso Joe	Chief Commercial Officer	Nov 15 '23	Sale	2.97	11,266	33,460	92,392	Nov 16 04:49 PM
Kohler Terry	Chief Financial Officer	Nov 15 '23	Sale	2.97	9,632	28,607	34,416	Nov 16 04:34 PM
Goldenberg Gary	Chief Medical Officer	Nov 15 '23	Sale	2.97	3,036	9,017	86,257	Nov 16 04:35 PM
Hayes Christopher G.	Chief Legal Officer	Nov 14 '23	Sale	2.93	22,141	64,873	134,784	Nov 16 04:32 PM
White Ted	President and CEO	Nov 14 '23	Sale	2.93	22,141	64,873	181,648	Nov 16 04:33 PM
Bonaccorso Joe	Chief Commercial Officer	Nov 14 '23	Sale	2.93	21,580	63,229	103,658	Nov 16 04:49 PM
Kohler Terry	Chief Financial Officer	Nov 14 '23	Sale	2.93	18,452	54,064	44,048	Nov 16 04:34 PM
Goldenberg Gary	Chief Medical Officer	Nov 14 '23	Sale	2.93	5,817	17,044	89,293	Nov 16 04:35 PM
Manning Paul B	Director	Jul 24 '23	Buy	5.02	200,000	1,004,000	7,851,128	Jul 24 06:47 PM
White Ted	President and CEO	Jul 24 '23	Sale	4.83	50,677	244,770	128,789	Jul 25 04:18 PM
Bonaccorso Joe	Chief Commercial Officer	Jul 24 '23	Sale	4.83	38,262	184,805	62,738	Jul 25 04:22 PM
Hayes Christopher G.	Chief Legal Officer	Jul 24 '23	Sale	4.83	33,789	163,201	81,925	Jul 25 04:25 PM
Goldenberg Gary	Chief Medical Officer	Jul 24 '23	Sale	4.83	28,699	138,616	70,110	Jul 25 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRCA

Verrica Pharmaceuticals Inc

Upgrade your FINVIZ experience